Compare CRTO & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | CMPX |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.6M | 927.5M |
| IPO Year | 2013 | 2020 |
| Metric | CRTO | CMPX |
|---|---|---|
| Price | $17.20 | $5.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $35.90 | $14.43 |
| AVG Volume (30 Days) | 275.2K | ★ 1.7M |
| Earning Date | 05-01-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.95 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $2,296,692,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.62 | $677.91 |
| P/E Ratio | $6.69 | ★ N/A |
| Revenue Growth | ★ 27.65 | N/A |
| 52 Week Low | $16.15 | $1.33 |
| 52 Week High | $36.06 | $6.88 |
| Indicator | CRTO | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 41.55 |
| Support Level | $16.15 | $4.86 |
| Resistance Level | $21.32 | $5.86 |
| Average True Range (ATR) | 0.71 | 0.29 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 21.63 | 36.26 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.